The Relevance of Monoclonal Antibodies in the Treatment of COVID-19
1
Department of Analytical Chemistry, Science Faculty, Biohealth Research Institute (ibs.GRANADA), University of Granada, E-18071 Granada, Spain
2
Department of Clinical Pharmacy, Biohealth Research Institute (ibs.GRANADA), San Cecilio University Hospital, E-18012 Granada, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Tatsuya Yamazaki
Vaccines 2021, 9(6), 557; https://doi.org/10.3390/vaccines9060557
Received: 26 April 2021
/
Revised: 18 May 2021
/
Accepted: 22 May 2021
/
Published: 26 May 2021
(This article belongs to the Collection Research on Monoclonal Antibodies and Antibody Engineering)
Major efforts have been made in the search for effective treatments since the outbreak of the COVID-19 infection in December 2019. Extensive research has been conducted on drugs that are already available and new treatments are also under development. Within this context, therapeutic monoclonal antibodies (mAbs) have been the subject of widespread investigation focusing on two target-based groups, i.e., non-SARS-CoV-2 specific mAbs, that target immune system responses, and SARS-CoV-2 specific mAbs, designed to neutralize the virus protein structure. Here we review the latest literature about the use of mAbs in order to describe the state of the art of the clinical trials and the benefits of using these biotherapeutics in the treatment of COVID-19. The clinical trials considered in the present review include both observational and randomized studies. We begin by presenting the studies conducted using non-SARS-CoV-2 specific mAbs for treating different immune disorders that were already on the market. Within this group of mAbs, we focus particularly on anti-IL-6/IL-6R. This is followed by a discussion of the studies on SARS-CoV-2 specific mAbs. Our findings indicate that SARS-CoV-2 specific mAbs are significantly more effective than non-specific ones.
View Full-Text
Keywords:
COVID-19 treatment; clinical trials; monoclonal antibodies; non-SARS-CoV-2 specific; SARS-CoV-2 specific
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Torrente-López, A.; Hermosilla, J.; Navas, N.; Cuadros-Rodríguez, L.; Cabeza, J.; Salmerón-García, A. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines 2021, 9, 557. https://doi.org/10.3390/vaccines9060557
AMA Style
Torrente-López A, Hermosilla J, Navas N, Cuadros-Rodríguez L, Cabeza J, Salmerón-García A. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines. 2021; 9(6):557. https://doi.org/10.3390/vaccines9060557
Chicago/Turabian StyleTorrente-López, Anabel, Jesús Hermosilla, Natalia Navas, Luis Cuadros-Rodríguez, José Cabeza, and Antonio Salmerón-García. 2021. "The Relevance of Monoclonal Antibodies in the Treatment of COVID-19" Vaccines 9, no. 6: 557. https://doi.org/10.3390/vaccines9060557
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
